Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Rolf Fendel

Rainer Fischer

Stefan Barth

Andreas Reimann

Torsten Klockenbring

Dominika Maskus

Stephanie Kapelski

The technology provided herein relates to novel human antibodies againstparasites, in particular against the malaria parasite. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. toschizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Anti-plasmodium parasite antibodies

The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against() comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Anti-parasitic complexes

The technology provided herein relates to novel human antibodies againstparasites, in particular against the malaria parasite. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. toschizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Growing community of inventors

Aachen, Germany

Rolf Fendel